Losartan Potassium Tablet, Film Coated
Product Images NDC 71335-1102

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71335-1102). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713351102)

Losartan Potassium 50 mg film-coated tablet label by Bryant Ranch Prepack. The label includes storage instructions to keep the drug out of reach of children and to store at room temperature (20°-25°C or 68°-77°F). It also references Cozaar 50 mg tablet by Hetero Labs Limited for comparison. The label displays a barcode and an NDC number 71335-1102-1.*

FDA Label Image

Lbl713351580

Losartan Potassium 100 mg film-coated tablet label from Bryant Ranch Prepack, containing 30 tablets. The label includes storage instructions to keep at room temperature between 20° and 25°C (68°-77°F) and a warning to keep out of reach of children. The label also references Cozaar 100 mg tablet by Hetero Labs Limited for comparison and displays the NDC 7133515801.*

FDA Label Image

Lbl713351582

Losartan Potassium 25 mg film-coated tablet label, packaged by Bryant Ranch Prepack. The label compares to Cozaar 25 mg tablet by Hetero Labs Limited. It includes storage instructions to keep at room temperature 20°-25°C (68°-77°F). The package quantity is #90 tablets. The label features a barcode and NDC 7133515821.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line chart comparing the percentage of patients with a primary endpoint over study months for Atenolol and Losartan Potassium. The graph shows adjusted risk reduction data, with time in months on the x-axis and percentage of patients on the y-axis, highlighting a 13% adjusted risk reduction for Losartan Potassium compared to Atenolol.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a 66-month study period between Losartan potassium and Atenolol. The x-axis represents study months, and the y-axis shows the percentage of patients with stroke. Losartan potassium demonstrates a lower incidence compared to Atenolol, with an adjusted risk reduction of 25% noted.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot figure displaying primary endpoint events within demographic subgroups for Losartan Potassium compared to Atenolol. The chart shows hazard ratios with 95% confidence intervals for primary composite outcomes and stroke (fatal/non-fatal) events, segmented by age, gender, race, ISH, diabetes, and cardiovascular disease history.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph depicting the percentage of patients with events over time (months) comparing Losartan Potassium and placebo. The graph includes a risk reduction value of 16.1% with a p-value of 0.022, showing the trends of event occurrence up to 48 months.*

FDA Label Image

Losartanstructure (Losartanstructure)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.